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Abstract
Background: Hepatitis B Virus (HBV) infection is one of  the major causes of  liver cirrhosis, hepatocellular carcinoma and 
deaths due to the acute or chronic consequences worldwide. HBV is distributed into various genotypes based on nucleic acid 
sequence variation.
Objectives: To develop a method of  HBV genotyping and drug resistance interpretation using partial sequencing of  polymerase 
gene.
Methods: This study was performed on 98 HBV infected patients’ serum samples from Western India. A nested PCR protocol 
was designed for amplification of  pol gene from HBV genome and Sanger’s sequencing of  the gene fragment. Sequences were 
aligned with HBV reference sequences for phylogenetic analysis and for characterization of  genetic diversity. Drug resistance 
mutations were screened using HBVSeq program from Stanford University.
Results: Distribution of  HBV genotypes showed predominance of  genotype D, circulating in 76 (77.55%) patients (p < 0.05). 
Genotypes A and C were less prevalent and were identified in 4 (4.08%) and 18 (18.37%) patients, respectively. Anti-retroviral 
drug resistance mutations were not detected in any patient.
Conclusion: A method for determination of  HBV genotypes using pol gene sequencing which simultaneously detects major 
drug resistance mutations has been established. HBV genetic diversity may play an important role in treatment decision.
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HBV infection is a major health care problem with up to 
400 million affected persons worldwide and accounts for 
one million deaths worldwide from cirrhosis, liver failure 
and hepatocellular carcinoma.1 HBV has been broadly 
classified into eight genotypes, designated as A-H.2 This 
classification is based on inter-genotypic divergence of  
at least 8% in the complete nucleotide sequence or more 
than 4% in the S gene.3 Evidence from various research 
studies has suggested that HBV genotypes may play some 
role in causing different disease profiles in chronic hep-
atitis B (CHB).4 Among Asians, who constitute greater 
than 75% of  the worldwide population of  individuals 
with CHB, genotypes B and C are the two most com-
mon HBV genotypes in Asia and Oceania.5 Genotype D 
is most widely distributed and found in Africa, Europe, 
Mediterranean countries, India, Indonesia and Nigeria.6
Correlation of  genotypes with severity of  infection has 
also been established. Researchers have found the asso-
ciation of  genotype C with more severe liver disease as 
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compared to genotype B and higher incidence of  HCC in 
genotype D infected patients.7 In Europe, most patients 
with genotype D are reported to have acute hepatitis B, 
while most patients with genotype A have chronic hep-
atitis B.8 Association study in patients on Lamivudine 
therapy showed that patients with genotype D achieved 
higher SVR (Sustained viral response) than with genotype 
A; hence response to therapy is also found to be ruled by 
genotypes.9 Due to these important findings, HBV geno-
typing has gained immense importance in guiding treat-
ment decisions, improving vaccination, and controlling 
liver diseases. Various methods of  genotyping are available 
of  which sequencing of  S gene was mostly performed in 
the previous studies. Ying et al., performed semi-nested 
PCR amplification (using three primers) of  pol gene and 
its sequencing for HBV genotyping in Chinese patients.10 
In this study, we used nested PCR that uses four prim-
ers that results in increased specificity. As this assay is 
performed on low viral load samples, it also underlines 
higher sensitivity of  nested PCR approach. Advances in 
molecular biology techniques have led to implementation 
of  real time PCR for detection of  HBV genotypes using 
melting curve analysis.11 This study comprises HBV poly-
merase gene sequencing covering YMDD region which 
also includes the overlapping S gene region, it was found 
that the sequence can be used to identify the genotype of  
the virus. This genotyping method makes use of  Sanger’s 
DNA sequencing technology to sequence HBV DNA 
polymerase region using different set of  primers to am-
plify the HBV DNA polymerase and overlapping S gene 
region. Along with genotyping of  Hepatitis B virus, this 
method also helps in determination of  drug resistance 





Four hundred and twenty seven chronic HBV infected 
patient serum samples were received at Molecular Diag-
nostic Lab of  geneOmbio Technologies Private Limited 
(Pune, India) during March 2012 to May 2014 from associ-
ated hospital laboratories located in Western Indian states 
of  Maharashtra, Goa and Gujrat. This was a retrospec-
tive cross-sectional study and all procedures conformed 
to the ethical guidelines of  the 1975 Helsinki Declaration. 
No personal identification information or other personal 
identifiers such as address or hospital identification num-
ber were recorded to ensure patient confidentiality. This 
study was approved ethically by the Institutional Review 
Board (IRB) of  geneOmbio Technologies (Approval No. 
IRB/2012/G-011) and Institutional Biosafety Commit-
tee (IBSC) at Dr. D. Y. Patil Vidyapeeth, Pune. The serum 
samples were collected and stored at -40°C until use.
Inclusion criteria
Patients with HBeAg and HBsAg positive sera confirmed 
by HbeAg/HbsAg Rapid Test Kit (Medical Biological 
Services, Italy) and having viral load in the range of  7- 
110000000 HBV DNA IU/mL were included. HBV viral 
load was determined using Roche COBAS TaqMan 48 
Kit on COBAS TaqMan 48 Analyzer (Roche Molecular 
Systems, USA).
Exclusion criteria
Patients positive for Hepatitis C virus (HCV) and Hu-
man Immunodeficiency virus (HIV) anti-body test were 
excluded from the study. Screening for HCV and HIV-1 
was done using commercially available HCV TRI DOT 
and HIV TRI DOT kit (J. MITRA &Co. Ltd., New Delhi, 
India). Patients having viral load undetectable or less than 
7 HBV DNA IU/mL were also excluded from the study. 
Of  the 427 samples, 140 patients were both HBeAg and 
HBsAg positive. Thirty eight of  these 140 patients had 
HBV viral load undetectable or less than 7 HBV DNA 
IU/mL, therefore were excluded from the study. Four 
samples were excluded due to co-infection with either 
HCV or HIV.
Hence this retrospective cross-sectional study examined 
only a total of  98 (70 males, 28 females, mean age 43.8 + 
11.6 years) patients.
Primer design
Twenty three full-length HBV sequences representing all 
of  the available HBV genotypes were downloaded from 
GenBank nucleotide sequence database (http://www.
ncbi.nlm.nih.gov). These sequences were selected from 
list provided by NCBI Genotyping tool (http://www.
ncbi.nlm.nih.gov/projects/genotyping) as reference 
set of  sequences for HBV genotyping. Using ClustalW 
multiple sequence alignment tool the reference sequenc-
es were aligned to find the conserved domains.12 First 
round PCR primers YMDDF1 (5’- CAAGGTATGTTG-
CCCGTTTG -3’) and YMDDR1 (5’-CCCAACTCCTC-
CCAGTCCTTAA-3’) were selected from previously 
published data.13,14 With the help of  Primer 3- Online 
Primer designing tool (http://primer3.ut.ee), we designed 
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a nested PCR primer pair YMDDF2 (5’ –CTGTATTC-
CCATCCCATCATC-3’) and YMDDR2 (5’-GACCCA-
CAATTCGTTGACATAC-3’). The primers were synthe-
sized at Eurofins Genomics Pvt. Ltd. (Bangalore, India). 
The amplified fragment of  the polymerase gene overlaps 
slightly with the S gene. First round PCR primers were 
expected to generate 1290 bp amplicons whereas the 
nested PCR primers were expected to generate 409 bp 
amplicons. Implementation of  nested PCR protocol en-
hances the sensitivity of  the assay as it can amplify sam-
ples having very low HBV DNA viral load.
DNA isolation, PCR and sequencing of  HBV poly-
merase gene
DNA isolation from serum samples was performed using 
High Pure Viral Nucleic Acid Kit (Roche Molecular Sys-
tems, USA) according to the manufacturer’s instructions. 
PCR amplification was performed using Platinum Taq 
DNA Polymerase (Invitrogen Corporation, USA).
The fragment of  the polymerase gene was amplified by 
nested PCR with two rounds of  amplification. Five mi-
croliter of  DNA isolated from each patient was added 
to a 20 µL PCR mixture. The PCR mix contained 2.5 
µl of  10x PCR buffer (100 mM Tris– pH 9.0, 500 mM 
KCl, 15mM MgCl2 and 0.1% Gelatin), 200 µM dNTPs, 1 
unit of  Platinum Taq DNA polymerase, 20 pM each of  
YMDDF1 and YMDDR1 primers for first round PCR 
and sterile nuclease free water to make a final volume of  
25 µl. The first round of  amplification was performed 
with an initial 5 min denaturing step at 95°C, followed 
by 30 cycles of  denaturing for 45 s at 94°C, annealing 
for 30 s at 60°C, and elongation for 1 min at 72°C, with 
a final extension period of  10 min at 72°C. The second 
round of  amplification was performed using 20 pM each 
of  YMDDF2 and YMDDR2 primers, with an initial 5 
min denaturing step at 94°C, followed by 30 cycles of  de-
naturing for 45 s at 94°C, annealing for 30 s at 55°C, and 
elongation for 30 s at 72°C, with a final extension period 
of  10 min at 72°C. The reaction products of  the nested 
PCR were visualized on a 2% (w/v) agarose gel stained 
with ethidium bromide. Purification of  nested PCR prod-
ucts was performed using Purelink PCR product purifi-
cation kit (Life technologies, USA). Automated DNA se-
quencing was performed using BigDye Terminator v3.1 
Cycle sequencing kit on 3130 Genetic Analyzer (Applied 
Biosystems, USA).  Nucleotide sequences were submitted 
to NCBI nucleotide sequence database GenBank.
Determination of  HBV Genotypes and phylogenetic 
analysis
NCBI HBV genotyping tool (http://www.ncbi.nlm.nih.
gov/projects/genotyping) was used for determination 
of  genotype for each HBV sequence. Nucleotide se-
quences of  336 bases generated after sequence quality 
trimming using Chromas Pro 1.34 (Technelysium Pty. 
Ltd., Queensland, Australia) were used for homology 
and phylogenetic analysis. Sequences were aligned by us-
ing the ClustalW program. Two representative reference 
sequences from each genotype were used for construc-
tion of  phylogenetic tree (A: AF418677, X51970; B: 
D23678, AB073838; C: D50489, Y18855; D: AB090270, 
AF151735; E: AB032431, X75657; F: AB036905, 
AB036907; G: AB064313, AB056513 and H: AY090454, 
AY090457). The alignment was converted in MEGA for-
mat using MEGA 6.06 software.15 The phylogenetic tree 
was constructed by the Maximum composite likelihood 
algorithm with a bootstrap test of  1000 replicates.16 
Significance of  polymerase gene fragment sequence for 
genotyping was evaluated by phylogenetic analysis of  ref-
erence sequences of  all genotypes (A-H) obtained from 
NCBI genotyping tool reference set and GenBank data-
base. This reference set includes total 66 sequences.
Genetic distance
An analysis of  the number of  base substitutions per site 
between the nucleotide sequences (genetic distance (d)) 
was conducted using the maximum composite likelihood 
method in MEGA 6.06 for reference sequences from 
each genotype used for phylogenetic analysis. Analyses 
were conducted using the Maximum Composite Like-
lihood model. The differences in the composition bias 
among sequences were considered in evolutionary com-
parisons. The analysis involved 16 nucleotide sequences. 
Similarity matrix was derived from the distance analysis.
Evolutionary substitution rates
Different genotypes are evolved due to substitution mu-
tations at different sites within the viral genome.17 To de-
termine the sites that are highly prone to substitutions, 
we performed the substitution rate analysis using MEGA 
6.06. Substitution pattern and rates were estimated under 
the Tamura-Nei (1993) model (+G).18 A discrete Gamma 
distribution was used to model evolutionary rate differ-
ences among sites (5 categories, [+G]).19
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Determination of  drug resistance mutations
Drug resistance interpretation based on mutation in HBV 
polymerase gene was inferred by submitting the sequence 
data to Stanford University database (http://hivdb.stan-
ford.edu/HBV/HBVseq) and Geno2pheno (hbv) resis-
tance prediction tool (http://hbv.geno2pheno.org) (Max 
Planck Institute)
Statistical analysis
Clinical characteristics, mean and frequency of  genotyp-
ing data were analysed using a SPSS statistics (2014) and 
Microsoft Excel (2013).  Descriptive statistics are present-
ed as proportions, means ± standard deviation, and me-
dians with interquartile range. Comparative analyses were 
performed using the Student’s t-test and Chi square test. 
A P value of  less than 0.05 was considered significant.
 
Results
Clinical characteristics of  study patients infected with 
HBV are provided in Table 1. All the patients were from 
state of  Maharashtra geographically located in Western 
India. Mean HBV viral load of  study samples was 4.46 + 
1.77 HBV DNA IU/mL.
Table 1. Clinical characteristics of study patients infected with Hepatitis B Virus 
 
Variables Population (n= 98) 
Age, years 43.8 + 11.6 
Male/Female, n (%) 70/28 (71.43%/28.57%) 
HBsAg, positive 98 (100%) 
HBeAg, positive 98 (100%) 
Serum ALT (U/L) + SD 86.10 + 32.54 
HBV DNA positive, n (%) 98 (100%) 
HBV viral load, log10 IU/mL 
(range, HBV DNA IU/mL) 
4.46 + 1.77 
(7- 110000000 HBV DNA IU/mL) 
 
PCR amplification of  HBV pol gene
Hepatitis B Virus DNA isolated from patients generat-
ed 409 bp PCR amplification product for pol gene using 
nested PCR approach (Figure 1). In total, all 98 (100%) 
samples were positive for polymerase gene fragments. 
Each of  these nested PCR reaction products were then 
sequenced. The nucleotide sequence data was submit-
ted to GenBank, these sequences are available at NCBI 
nucleotide sequence database with accession number 
KM076939-KM077016.
Figure 1. Agarose gel electrophoresis (2% w/v) of  the nested PCR products and DNA marker. 
200 bp DNA ladder (Lane M), second round of  amplification products (Lane 1-8).
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Determination of  HBV genotypes and phylogenetic 
analysis
Three major genotypes A, C and D were found within the 
study population as predicted by NCBI genotyping tool 
for HBV. HBV Genotype D (n=76; 77.55%) was found 
to be predominant circulating genotype (p < 0.05), fol-
lowed by C (n=18; 18.37%) and A (n=4; 4.08%) among 
98 sequences. Geno2pheno and HBVSeq Programs also 
determined genotypes and subgenotypes of  the sequenc-
es. Six sub-genotypes were detected A1, C1, C2, D2, 
D3 and D4, of  which HBV sub-genotypes D2 (n=65; 
66.33%). Clinical and demographic characteristics of  the 
study population with respect to sub-genotypes distri-
bution are provided in Table 2. Higher levels of  Serum 
ALT (110.33 +42.54 U/L) were observed in sub-geno-
types A1. Genotype prediction from NCBI genotyping 
tool, Geno2Pheno and HBVSeq produced 100% similar 
results.
Table 2. Clinical and demographic characteristic of the study population  
with respect to subgenotypes distribution 
 
Genotype A (n=4) C (n=18) D (n=76) 
Subgenotype A1 C1 C2 D2 D3 D4 
Number of samples (%) 4 (4.08) 7 (7.14) 11 (11.22) 65 (66.33) 1 (1.02) 10(10.20) 











Age , years (range) 38.0 + 11.69 41.57 +  5.32 43.36 + 8.49 45.12 + 12.65 49.0 + 0.00 39.3 + 10.88 
Serum ALT (U/L) 
(range) 110.33 + 42.54 96.52 + 40.20 86.00 + 30.51 82.57 + 31.96 72.00 + 0.00 93.57 + 30.31 
HBV viral load, 
log10 copies/mL (range) 4.17 + 1.44 4.70 + 2.03 3.22 + 1.27 4.51 + 1.77 3.25 + 0.00 5.55 + 1.71 
Common Mutations 

















Phylogenetic analysis based on alignment of  nucleotide 
sequences of  HBV polymerase gene from 78 study sam-
ples and 16 representative reference sequences (NCBI 
GenBank database) was used to confirm the presence 
of  genotype A, C and D. As evident from phylogenetic 
tree presented in Figure 2, Genotype A, C and D samples 
clustered with closest reference sequences of  the same 
genotype. The evolutionary history was inferred using 
the UPGMA method. Phylogenetic analysis of  66 ref-
erence sequences obtained from NCBI GenBank data-
base showed distinct clustering of  each genotype proving 
the significance of  use of  polymerase gene fragment se-
quence in HBV genotyping. 
Table 2. Clinical a e ographic characteristic of the study p pulation  
with res t to sub-genotypes distribution. 
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Figure 2. Phylogenetic analysis of  Hepatitis B Virus (HBV) based on partial sequence of  polymerase gene from 78 
study samples and 16 reference sequences representing each genotype. Numbers at respective nodes represent per-
centage bootstrap values (1000 replicates).  The Maximum-Likelihood tree was constructed with a substitution model 
of  Tamura-Nei plus gamma distribution using MEGA software 6.06. As the branch lengths and bootstrap values 
between various genotype D sequences were low or zero, the tree has been represented in topology view to make 
ancestor-descendant relationship clear, hence the scale bar was removed.
Figure 3 shows distinct branches for each genotype sup- ported by significant bootstrap values.
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Figure 3. Phylogenetic analysis of  66 reference sequences for polymerase gene obtained from NCBI GenBank database using Maxi-
mum-Likelihood Method. Branch reliability is indicated by the percentage of  bootstrap values at each node (1,000 replications). The scale bar 
indicates the number of  base substitutions per site.Lower rectangle represent each genotype distributed amongst branches within the tree.
 
Genetic distances
When all eight genotypes were compared to each oth-
er (Table 3), HBV genotypes showed genetic divergence 
ranging from 6.7 (genotype A B) to 18.4 (genotype C   
H) based on sequence polymorphism in polymerase gene. 
The nucleotide sequence similarity ranged from 81.6 
(genotype C    H) to 93.3 (genotype A   B). This 
analysis included two sequences for each genotype hence 
inter-genotypic and intra-genotypic divergence was also 
determined.
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Evolutionary substitution rates
All sequences were distributed under five different Gam-
ma categories based on the sequence divergence and 
types of  substitutions. Mean evolutionary rates in these 
categories were 0.00, 0.05, 0.25, 0.90, 3.80 substitutions 
per site. The nucleotide frequencies were A = 25.03%, T 
= 34.81%, C = 19.43%, and G = 20.73%. For estimating 
ML values, a tree topology was automatically computed. 
The maximum Log likelihood for this computation was 
-2972.224.  The estimated value of  the shape parameter 
for the discrete Gamma Distribution is 0.2961. These nu-
cleotide substitution rates are scaled such that the average 
evolutionary rate across all sites is 1. This means that sites 
showing a rate < 1 are evolving slower than average. Nu-
cleotide positions with substitution rate less than 1 (Mean 
(relative) evolutionary rate <1) were 237/336 whereas the 
number of  sites with >1 substitution rate (Mean (relative) 
evolutionary rate >1) were 99/336. Hence the sequence 
studied has 29.46% nucleotide positions which are evolv-
ing faster than average.
HBV drug resistance interpretation
Genotypic resistance mutations against lamivudine 
(L180M, M204V/I), adefovir (A181T, N236S), and en-
tecavir (I169M, A184T/V, S202I/G, M250V/I/L) were 
not detected in any patient. Genotypic variants were de-
tected as other mutations that may not be responsible for 
drug resistance. The mutations with greater than 5% inci-
dence rate in study population have been provided along 
with their frequency in Table 4.  Mutation at 248th amino 
acid (N248H) of  DNA polymerase gene was the most 




































































AB090270 97.7 88.9 89.2 90.5 91.5 88.8 88.9 86.9 87.5 90.2 91.4 84.1 84.1 83.2 83.9
AF151735 2.3 87.9 88.2 89.3 89.6 86.9 86.9 84.5 85.2 89.6 90.2 83.8 83.8 82.6 83.2
G
AB064313 11.1 12.1 99.7 89.3 89.3 89.2 88.6 86.3 86.7 88.6 88.6 81.7 81.7 82.1 82.5
AB056513 10.8 11.8 0.3 89.6 89.6 89.6 88.9 86.4 87.0 88.3 88.9 82.1 82.1 82.5 82.9
A
AF418677 9.5 10.7 10.7 10.4 96.6 92.7 92.7 90.5 90.2 91.8 93.4 85.5 85.5 85.3 85.6
X51970 8.5 10.4 10.7 10.4 3.4 93.3 93.3 90.2 89.8 91.2 92.7 85.5 85.5 85.9 86.3
B
D23678 11.2 13.1 10.8 10.4 7.3 6.7 98.3 91.1 90.5 90.2 91.8 83.7 83.7 84.4 84.7
AB073838 11.1 13.1 11.4 11.1 7.3 6.7 1.7 91.1 90.8 90.2 91.8 83.7 83.7 84.8 85.1
C
D50489 13.1 15.5 13.7 13.6 9.5 9.8 8.9 8.9 97.5 88.9 89.9 82.8 82.8 82.0 82.3
Y18855 12.5 14.8 13.3 13.0 9.8 10.2 9.5 9.2 2.5 87.6 88.9 83.2 83.2 81.6 82.0
E
AB032431 9.8 10.4 11.4 11.7 8.2 8.8 9.8 9.8 11.1 12.4 97.4 84.1 84.1 82.9 82.9
X75657 8.6 9.8 11.4 11.1 6.6 7.3 8.2 8.2 10.1 11.1 2.6 84.8 84.8 83.6 84.3
F
AB036907 15.9 16.2 18.3 17.9 14.5 14.5 16.3 16.3 17.2 16.8 15.9 15.2 100.0 89.6 90.2
AB036905 15.9 16.2 18.3 17.9 14.5 14.5 16.3 16.3 17.2 16.8 15.9 15.2 0.0 89.6 90.2
H
AY090454 16.8 17.4 17.9 17.5 14.7 14.1 15.6 15.2 18.0 18.4 17.1 16.4 10.4 10.4 99.4
AY090457 16.1 16.8 17.5 17.1 14.4 13.7 15.3 14.9 17.7 18.0 17.1 15.7 9.8 9.8 0.6
Table 3. Nucleotide sequence similarity and divergence of  polymerase gene among 
HBV genotypes reference sequence obtained from NCBIGenBank database
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Table 4. The mutations in HBV polymerase gene of study samples 
with greater than 5% incidence rate 
 
Mutation Site Number  of patients with mutation (% Rate) 
N248H 32  (32.65) 
I253V, D263E 16 (16.33) 
E271D, V253I 10 (10.20) 
Q267L, I266R 7  (7.14) 
I282V, N226H, S213T, I266T, S219A 6 (6.12) 
Q267H, C256G, N238H, D263S 5  (5.10) 
  
Discussion
Traditional HBV genotyping methods using restriction 
fragment length polymorphism (RFLP) have been de-
veloped and used extensively for HBV genotypes A to 
H.20 Genotyping methods that use multiplex PCR with 
type-specific primers have also been reported.13 However, 
most of  these newer methods are based on analyzing the 
S gene. Here we employed genotyping method based on 
a segment of  the HBV DNA polymerase gene.
This study demonstrated that using HBV DNA poly-
merase gene sequence all the different genotypes show 
distinct clades in phylogenetic analysis and hence the gene 
fragment used for analysis is a suitable target for HBV 
genotyping. As evident from phylogenetic tree, based on 
the clusters formed by genotypes A-H, the sequences ob-
tained from HBV DNA polymerase gene from patients 
can be classified under these genotypes.
In this study, the predominant genotype of  Hepatitis B 
was found to be genotype D, and there were no patients 
with drug resistant HBV. As per previous reports, geno-
type C is less reported in India, however we found 18 out 
of  98 cases to be genotype C which indicates substantial 
increase in infections with genotype C in Indian popula-
tion.21 The variation in relative frequency of  HBV geno-
types reported in studies from India by various authors 
have confirmed that the genotype D has been predom-
inant among others.22 Therefore, the fragment of  HBV 
DNA polymerase gene as a target for genotyping hep-
atitis B in India has been proved to be significant. This 
genotyping method can also be used to predict antiviral 
therapeutic response among HBV genotypes and the 
development of  drug resistance due to mutations. The 
fragment covers clinically important YMDD domain of  
polymerase gene, mutations which are responsible for 
failure of  anti-viral therapy. Hence using the same se-
quence data, interpretation of  drug resistance in HBV is 
possible. It is a valuable tool for guiding the treatment of  
lamivudine-resistant HBV in different clinical settings.23 
Nucleotide sequence analysis of  HBV DNA polymerase 
gene in all patient samples using different genotyping al-
gorithms detected genotypes A, C and D whereas geno-
types B, E, F, G and H were not detected.
Of  the eight genotypes of  HBV, infection with HBV 
genotype D is the most common in India.  Infection with 
genotype D is associated with more severe liver disease 
than genotype A.24 The major route of  HBV transmis-
sion in acute hepatitis seem to be sexual intercourse, fre-
quent international travel and contact with people from 
different ethnic backgrounds, which may contribute to 
change in the predominance pattern of  genotypes in a 
geographical location.25 This study demonstrated that the 
patients suffering from HBV infection were infected with 
different genotypes as D, C and A, suggesting no signifi-
cant change in predominance of  HBV genotype in hepa-
titis B infected cases.
Drug resistant viral strains are evolved due to increased 
use of  anti-viral drugs to treat chronic hepatitis B, such as 
lamivudine, adefovir, telbivudine, and entecavir.26 In ab-
sence of  anti-viral drugs and drug pressure, most of  the 
drug resistant mutants do not survive and may not remain 
as fit as the wild type virus in an acutely infected liver.27,28 
In contrast, natural resistance mutations in treatment-na-
ive chronic hepatitis B patients may exist. Mutation sub-
stitution rates in polymerase gene as per our study reveal 
the number of  nucleotide position which are more prone 
to mutations indicating that such changes may drive inci-
dence of  drug resistance as well as different genotypes. 
Our study was limited to genotype D, C and A due to 
non-availability of  samples from other genotypes, larger 
studies that include samples from patients with all HBV 
genotypes are required to represent data for all genotypes.
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Conclusion
The study reports Hepatitis B Virus genotyping using 
DNA polymerase gene fragment sequencing as an ef-
fective tool to determine the HBV genotypes as well as 
drug resistance mutations in HBV infected patients. This 
study reports high prevalence of  genotype D which is in 
concordance with previous studies. It provides a useful 
alternative to complete sequencing of  the HBV genome 
and allows the study genetic variation between various 
genotypes and drug resistance mutations responsible 
for anti-viral drug failure.  Genotyping data of  HBV 
via sequence of  DNA polymerase fragment from vari-
ous geographical population can be generated to validate 
this method in different populations. One of  the studies 
reported from China demonstrated the significance of  
HBV DNA polymerase gene sequencing based genotyp-
ing and drug resistance interpretation.10 Future studies in 
patients at different stages of  infection and therapeutic 
treatment would help us in understanding the relevance 
of  genotype, resistance mutations and response of  the 
patient to a particular therapy. These studies can be car-
ried out to investigate the clinical, virological and thera-
peutical response characteristics of  HBV genotypes, with 
clinical data such that the status of  HBV infection can be 
characterized (carrier, immunotolerant, acute and chronic 
hepatitis, cirrhosis) using a large population size.
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